ITLN1 and benign prostatic hyperplasia: Despite documented anti-inflammatory, anti-obesity, and anti-diabetic properties observed in various populations (Tan et al. 2010; Watanabe et al. 2017), the precise role of ITLN-1 in the pathogenesis of BPH remains unclear.